MUC-1 mucin assays for monitoring therapy in metastatic breast cancer

Breast

Volumn 7, Issue 4, 1998, Pages 181-186

  Graves, R ^a   Hilgers, J ^b   Fritsche, H ^c   Hayes, D ^d   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MUCIN; TUMOR MARKER;

BIOASSAY; BIOLOGICAL MONITORING; BREAST METASTASIS; CLINICAL FEATURE; EPITOPE MAPPING; IMMUNOASSAY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW;

EID: 0031718016     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(98)90105-9     Document Type: Review

References (31)

1. Price M R. High molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol 1988; 24: 1799-1804.
2. Price M R, Tendler S J B. Polymorphic epithelial mucins (PEM): molecular characteristics and association with breast cancer. The Breast 1993; 2: 3-7.
3. Hilkens J, Buijs F, Hilgers J, Hageman Ph, Calafat A, Sonnenberg A, van der Valk M A. Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984; 34: 197-206.
4. Koldovsky U, Wargalla U, Hilkens J, Taylor-Papadimitriou J, Schnuerch H G, Hilgers J. Reactions of monoclonal antibodies against membranes of human milk fat globules with uterine and cervical epithelia during proliferative and secretory stages. Prot Biol Fluids 1984; 32: 239-242.
5. Hayes D, Sekine H, Ohao T, Abe M, Keefe K, Kufe D W. Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-1678.
6. Robertson J F R, Pearson D, Price M R et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 1990; 26: 1127-1132.
7. Price M R, Rye P D, Petrakou E et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biology 1998; 19: 1-20.
8. Schol D J, Meulenbroek M F A, Snijdewint F G M et al. Epitope fingerprinting using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol 1998; 19: 35-45.
9. Spencer D I R, Price M R, Tendler S J B et al. Effect of glycosylation of synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies. Cancer Letters 1996; 100: 11-15.
10. Verstraeten A A, Bon G G, Kenemans P, Van Kamp G J, Hilgers J. Diagnostic and prognostic significance of the mucin serum tumor marker CA M26 and CA M29: theoretical considerations based on a review of the literature. In: A Balesta, G C Torre, E Bombardieri, M Gion, R Molina (eds). Updating on tumor markers in tissue and biological fluids: basic aspects and clinical applications. Torino: Edizione Minerva Medica, 1993; pp. 575-587.
11. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 1996; 42: 564-575.
12. Van Dalen A, Heering K J, Barak V et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumor marker changes. The Breast 1996; 5: 82-88.
13. Dnistrian A M, Schwartz M K, Greenberg E J, Schwartz D C. BR 27.29 as a marker in breast cancer. J Tumor Marker One 1995; 10: 91-97.
14. Beveridge R, Chan D, Muss I L. Serial changes of serum CA 27.29 antigen predicts progression or remission in Stage IV breast cancer. J Clin Oncol 1997; 16: 146.
15. Robertson J F R, Pearson D, Price M R, Selby C, Blarney R W, Howell A. Objective measurement of therapeutic response in breast cancer using serum markers. Br J Cancer 1991; 64: 757-763.
16. Reddish M A, Helbrecht N, Almeida A F, Madiyalakan R, Suresh M R, Longenecker B M. Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen, MUC1. J Tumor Marker Oncol 1992; 7: 19-27.
17. Murray A, Robertson J F R, Price M R. Analysis of the temporal compressibility of breast tumor marker assays: development of a 'near patient' assay. Int J Biol Markers 1995; 10: 200-205.
18. Hilgers J, Nustadt K (Chairmen). TD4 Workshop Report of the International Society of Oncodevelopmental Biology and Medicine (ISOBM). Analysis of 56 monoclonal antibodies against the MUC-1 mucin. Tumor Biol 1997; 19: 1-152.
19. Roth H J, Zahn I, Maimonis P. Performance characteristics of the ACS™ BR: a comparison with three other assays that also measure CA 15-3. Clin Lab 1995; 41: 1031-1035.
20. Bon G G, von Mensdorff-Pouilly S, Kenemans P et al. Clinical and technical evaluation of ACS™ BR serum assay of MUC1 genederived glycoprotein in breast cancer and comparison with CA 15-3 assays. Clin Chem 1997; 43: 585-593.
21. Cheli C D, Morris D L, Kish L et al. Bayer Immuno 1™ CA 15-3 assay: a highly precise and fully automated immunoassay for longitudinal monitoring of CA 15-3 antigen levels in serum. Clin Chem (in press).
22. Dnistrian A M, Schwartz M J, Greenberg E J, Smith C A, Schwartz D C, Maimonis P. Evaluation of a breast cancer antigen assayed on the Ciba Corning ACS 180® automated chemiluminescence system. J Tumor Marker Oncol 1996; 11: 5-10.
23. Hayes D F. Tumor markers for breast cancer: current utilities and future prospects. In: Hayes D F. Hematology/Oncology Clinics of North America: Tumor Markers in Adult Solid Malignancies. Philadelphia: WB Saunders Co, 1994: 485-506.
24. Molina R, Jo J, Zanon G et al. Utility of c-erbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15-3. Br J Cancer 1996; 74: 1126-1131.
25. Volas G, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum c-erbB2 levels in patients with breast cancer. Cancer 1996; 78: 267-272.
26. Williams M R, Turkes A, Pearson D, Griffiths K, Blamey R W. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer 1990; 61: 126.
27. Robertson J F R, Pearson D, Price M et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 1991; 33: 403-410.
28. Dixon A, Jackson L, Chan S, Badley R, Blarney R W. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer 1993; 68: 181-185.
29. Robertson J F R, Kramer S, Syzmendera J J. Guiding systemic therapy in metastatic breast cancer by blood tumour markers. British Cancer Research and Treatment 1997; 46: 63.
30. Hayes D F, Kiang D T, Korzun A, Tondini C, Wood W, Kufe D. CA 15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 38a.
31. Yasasever V, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on 'spiking' phenomena. Clin Biochem 1997; 30: 53-56.